Hepatic Vasculopathy and Regenerative Responses of the Liver in Fatal Cases of COVID-19.

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infects the nasopharynx and lungs and causes coronavirus disease-2019 (COVID-19). It may impact the heart, brain, kidney, and liver.1 Although functional impairment of the liver has been correlated with worse clinical outcomes, little is known about the pathophysiology of hepatic injury and repair in COVID-19.2,3 Histologic evaluation has been limited to small numbers of COVID-19 cases with no control subjects2,4 and demonstrated largely heterogeneous patterns of pathology.2,3.

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infects the nasopharynx and lungs and causes coronavirus disease-2019 (COVID-19). It may impact the heart, brain, kidney, and liver. Although functional impairment of the liver has been correlated with worse clinical outcomes, little is known about the pathophysiology of hepatic injury and repair in COVID-19. , Histologic evaluation has been limited to small numbers of COVID-19 cases with no control subjects , and demonstrated largely heterogeneous patterns of pathology. ,

Methods

Liver tissues of 60 patients who died of COVID-19 pneumonia were obtained from complete autopsies performed in Hamburg between March and June 2020. A cohort of 13 patients with fatal pneumonia in the absence of SARS-CoV-2 infection served as control subjects.

Hematoxylin and eosin staining and immunohistochemistry were applied to comprehensively evaluate the pathophysiology and regeneration aspects at the level of the hepatic microarchitecture. Label-free coherent Raman scattering and second harmonic generation imaging visualized major morphologic changes, revealing steatosis and dilatation of sinusoids.

Results

There were no significant differences in the patient characteristics except for preexisting neurologic conditions (P = .04) (Supplementary Table 1). Only 5 patients with COVID-19 and 1 control subject had history of liver disease. A minority of patients in the COVID-19 group (17%) received intensive care at the time of death with a trend within that group toward home or nursing home care, when compared with control subjects (Supplementary Table 1).

Supplementary Table 1

Clinical Characteristics and Autopsy Findings in COVID-19 Pneumonia and the Control Patient Group of Fatal Cases of Pneumonia Unrelated to SARS-CoV-2

	Classification	COVID-19 negative	COVID-19 positive	P value
		n = 13	n = 60
		n = 13	n = 60
Gender				.347
	Female	31 (4)	45 (27)
	Male	69 (9)	55 (33)
Age, y				.422
	≤80	54 (7)	42 (25)
	>80	46 (6)	58 (35)
Liver disease in medical history		8 (1)	8 (5)	.939
Heart disease in medical history		85 (11)	93 (56)	.299
Lung disease in medical history		77 (10)	63 (38)	.349
Neurologic disease in medical history		15 (2)	47 (28)	.038
Renal disease in medical history		46 (6)	33 (20)	.381
Oncologic disease in medical history		8 (1)	22 (13)	.246
Level of care at time of death				.096
	Home/nursing home	23 (3)	32 (19)
	Hospital, low care	31 (4)	52 (31)
	Intensive care unit	46 (6)	17 (10)
Autolysis of hepatic tissue				.171
	None	31 (4)	45 (27)
	Little	31 (4)	37 (22)
	Moderate	39 (5)	18 (11)
Liver tissue: SARS-CoV-2 and/or nucleocapsid-protein	Positive	0 (0)	22 (13)	.043
Sinusoidal platelet aggregates	Present	39 (5)	70 (42)	.031
Sinusoidal ectasia				.024
	None	39 (5)	25 (15)
	Focal (<25%)	15 (2)	7 (4)
	Multifocal (25%–75%)	39 (5)	20 (12)
	Diffuse (>75%)	8 (1)	48 (29)
Portal ectasia				.002
	None	8 (1)	3 (2)
	Focal (<25%)	46 (6)	13 (8)
	Multifocal (25%–75%)	31 (4)	25 (15)
	Diffuse (>75%)	15 (2)	5 (35)
Portal fibrosis				.293
	Widen, no septae	53 (7)	72 (43)
	Widen with septae	15 (2)	5 (3)
	Incomplete cirrhosis	31 (4)	22 (13)
	Cirrhosis	0 (0)	2 (1)
Confluent necrosis				.175
	None	85 (11)	66 (38)
	Focal	8 (1)	10 (6)
	Moderate	0 (0)	5 (3)
	Frequent	8 (1)	19 (11)
Apoptosis (cell count per field view)				.838
	0–1	77 (10)	81 (47)
	2–4	23 (3)	12 (7)
	>5	0 (0)	7 (4)
Hepatic steatosis				.046
	<5%	62 (8)	22 (13)
	5%–33%	15 (2)	38 (23)
	34%–66%	8 (1)	27 (16)
	>66%	15 (2)	13 (8)
Macrovesicular steatosis	Positive	39 (5)	67 (40)	.058
Microvesicular steatosis	Positive	39 (5)	75 (45)	.010
Kupffer cell siderosis				.771
	None	85 (11)	88 (53)
	Little	15 (2)	7 (4)
	Moderate	0 (0)	3 (2)
	Severe	0 (0)	2 (1)
Hepatocyte siderosis				.720
	None	92 (12)	88 (53)
	Little	0.00 (0)	8 (5)
	Moderate	8 (1)	2 (1)
	Severe	0 (0)	2 (1)
Ductular reaction (CK7)	Positive	77 (10)	87 (52)	.348
Cholestasis (histologically)	Positive	0 (0)	3 (2)	.793
EpCam+ regenerative cluster	Positive	11 (1)	29 (17)	.262
EpCam+ hepatic stem/progenitor cells (count per 10 field views)				.020
	<5	22 (2)	3 (2)
	5–24	56 (5)	31 (18)
	25–50	11 (1)	48 (28)
	>50	11 (1)	19 (11)

NOTE. Data given are % (n). P value: bold < .05.

Quantitative real-time polymerase chain reaction and in situ hybridization revealed viral RNA and replicative intermediates in liver tissues. Viral nucleocapsid protein was detected in hepatic stem/progenitor cells (HSPC), cholangiocytes, and hepatocytes (Figure 1 A). SARS-CoV-2 was detected at the RNA and/or protein level in 25% of livers in COVID-19 patients (Supplementary Table 1). Quantitative real-time polymerase chain reaction demonstrated 2 out of 5 bile samples positive for SARS-CoV-2 (data not shown).

Figure 1

Microvascular pathology and regenerative responses in livers of COVID-19 patients. SARS-CoV-2 replication, histopathology, and regeneration responses of the liver in fatal COVID-19. (A) Viral replication. SARS-CoV-2 viral RNA (“viral RNA”; +strand, brown dots indicated by black arrows) detected by in situ hybridization and replicative viral intermediates (“viral replication”; -RNA, brown dots indicated by black arrows). Immunohistochemistry shows immunoreactivity against viral nucleocapsid protein (red) in hepatocytes within acinar zones I and II, periportal HSPC, cholangiocytes of portal bile ducts, and premature hepatocytes along the canal of Hering. (B) Microvascular pathology. Sinusoidal platelet aggregates and thrombi (anti-CD42b staining), frequent in COVID-19 patients. Sinusoidal dilatation is noted in hematoxylin and eosin (HE) staining. Coherent Raman scattering microscopy provided label-free contrast for tissue structure (grey) and lipid droplet identification (yellow), whereas second harmonic generation provided contrast for collagen fibers (blue). (C) Liver injury. High levels of hepatocyte steatosis in COVID-19 patients, in comparison with control subjects, as detected by HE staining and coherent Raman scattering/second harmonic generation (lipid droplets in yellow and collagen in blue). White arrows indicate macrovesicular steatosis, whereas black arrows show microvesicular steatosis. (D) Intrahepatic stem cell niche. Drawing of the bipotent intrahepatic stem cell compartment, which is located in the canal of Hering. On severe hepatic injury HSPC emerge and expand, contributing to liver repair. HSPC are detected as single cells (indicated by black arrows) or in regenerative clusters comprised of EpCAM+ HSPC, hepatobiliary intermediate cells, and premature hepatocytes, which are adjacent to the canal of Hering. Stem cell marker EpCam (red) is also expressed by numerous HSPC and intermediates of hepatocytes/cholangiocytes and regenerative clusters of periportal hepatocytes of irregular size and shape. HSPC frequency in column diagram represents numbers of HSPC per 10 field views. ∗P < .05.

Sinusoidal platelet-aggregates were predominantly observed in the hepatic microvasculature of COVID-19 patients when compared with control subjects (70% vs 30%; P = .032) (Figure 1 B). Likewise, sinusoidal (P = .024) (Figure 1 B) and portal dilatation were observed (P = .002) (Supplementary Table 1). Hepatic microvascular thrombosis in COVID-19 patients was predominantly observed in nonhospitalized patients (32%; not receiving anticoagulant therapy), when compared with general in-patients (3%) and those requiring intensive care (10%; P = .016; data not shown).

COVID-19 patients demonstrated more hepatic steatosis (P = .046), mainly the microvesicular variant (P = .01), when compared with SARS-CoV-2-negative control subjects (Figure 1 C). Severe intrahepatic injury was associated with the activation of the intrahepatic stem cell niche along the canal of Hering (Figure 1 D), resulting in regenerative clusters of EpCAM+HSPC, hepatobiliary intermediate cells, and premature hepatocytes (Figure 1 D). Increased numbers of EpCAM+HSPC were observed alone, and in regenerative clusters, in patients with COVID-19, when compared with control livers (>25 HSPC/10 field views: 66% vs 22%; P = .020) (Figure 1 D).

Discussion

We show here secretion of virus into bile and that replication of SARS-CoV-2 occurs in liver tissues during COVID-19. Viral infection of HSPC was observed, comparable with that noted in lung alveolocyte progenitors in the first variant of SARS-CoV infections.

The major pathologic finding is that microvascular changes and platelet-rich thromboembolic phenomena reflect disordered thromboregulation and vascular insults as described previously. , As noted with other prothrombotic features of SARS-CoV-2 infections, , our observation of microthrombotic pathology predominantly occurring at time of death in nonhospitalized patients suggests that early initiation of anticoagulant therapy in those hospitalized may attenuate microvascular disease of the liver.

Platelet activation, sinusoidal injury, and parenchymal damage result in necrosis, which may be combined with predominantly microvesicular hepatocyte steatosis. Previous reports on postmortem evaluations have demonstrated hepatic steatosis to variable degrees in COVID-19 and seem to demonstrate macrovesicular over microvesicular forms of steatosis. ,

We demonstrate that vascular injury is accompanied by activation of the intrahepatic stem cell compartment showing features of aberrant regeneration. Similar scenarios of HSPC activation, correlating with the extent of liver cell necrosis, as noted here, have been also shown in hepatitis B–mediated liver injury.

We conclude that SARS-CoV-2 infects the liver as part of systemic illness and results in substantial microvascular thrombotic disease, organ injury, and attempts at regeneration.